Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;32(2):239-44.
doi: 10.1038/aps.2010.193.

The effect of the fibrinolytic enzyme FIIa from Agkistrodon acutus venom on acute pulmonary thromboembolism

Xi Lin  1 , Xiu-xia Liang, Jian-jun Tang, Jia-shu Chen, Peng-xin Qiu, Guang-mei Yan
Affiliations

The effect of the fibrinolytic enzyme FIIa from Agkistrodon acutus venom on acute pulmonary thromboembolism

Xi Lin et al. Acta Pharmacol Sin. 2011 Feb.

Abstract

Aim: To evaluate the effects of the fibrinolytic enzyme FII(a) from Agkistrodon acutus venom on acute pulmonary thromboembolism (APT) in animal models.

Methods: Both rabbit and dog APT models were used. For the rabbit APT model, the thrombi weight before and after administration was measured. Central venous pressure (CVP) and mean arterial pressure (MAP) were measured before and 15, 30, 60, and 120 min after the injection of the blood clot. Partial thromboplastin time (APTT), prothrombin time (PT), platelet count, and fibrinogen concentration were measured using auto analyzers. Plasminogen activity was measured based on chromogenic substrates. In the dog APT model, pulmonary blood flow was recorded using pulmonary angiography.

Results: Intravenous administration of FIIa (0.1-5.0 mg/kg) improved the APT-induced hemodynamic derangements and reduced thrombi weight. The angiography evidence also showed that the pulmonary emboli had almost disappeared after FII(a) infusion. FII(a) (0.1, 0.5, or 1.0 mg/kg) did not impair the coagulation pathways, although very high doses of FII(a) (5.0 mg/kg) could stimulate the production of plasminogen and result in impairment of the pathways.

Conclusion: FII(a) could effectively protect against APT via degradation of thrombi with less activation of plasminogen, and may provide a novel fibrinolytic enzyme for targeting the main pathological processes of the disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of embolization and thrombolytic agents on mean arterial pressure (MAP, A) and central venous pressure (CVP, B). The data demonstrate that (1) embolization leads to an increase in CVP and a decrease in MAP and (2) FIIa and urokinase consistently ameliorate the hemodynamic derangements.
Figure 2
Figure 2
Effect of FIIa on thrombi weight in rabbits (n=10 in each group). Dose-dependent reduction in thrombus weight by FIIa infusion. Data were expressed as mean±SEM. bP<0.05, compared with embo-control.
Figure 3
Figure 3
Digital subtraction angiography in APT. Arrows indicate thrombi in the right pulmonary artery. (A) Before pulmonary thromboembolism; (B) Two hours after pulmonary thromboembolism. The right pulmonary artery shows a complete obstruction. (C) FIIa treatment for 30 min. A reduction in obstruction was detected in the lower lobar pulmonary artery branches. (D) FIIa treatment for 60 min. The pulmonary emboli almost completely disappeared.
See this image and copyright information in PMC

References

    1. Keymel S, Rassaf T, Kelm M. Nitrite in action: a commentary on “Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboemolism. Free Radic Biol Med. 2006;41:1750–2. - PubMed
    1. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19–25. - PubMed
    1. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Lancet. 1999;353:1386–9. - PubMed
    1. Barritt DW, Jordon SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1:1309–12. - PubMed
    1. Hull R, Delmore T, Centon E, Hirsh J, Gent M, Sackett D, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855–8. - PubMed

Publication types